pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
iron · news · pharmadog
← back to iron
News mentioning iron
40
stories
2d
Priavoid’s Alzheimer’s pill fails to prove efficacy in phase 2 trial
fiercebiotech
3d
Marrow sets out to challenge genetic medicines for severe blood diseases
biopharma dive
15d
STAT+: As more doctors consult chatbots, health systems can block them — or buy in
stat
16d
Top health takeaways from the midterm elections
stat
17d
STAT+: Amid Mass General Brigham layoffs, CEO pens vague letter, stirring staff anxiety
stat
22d
Opinion: Health care needs buyers willing to say no
stat
22d
Politicians have failed to tackle health care affordability. It’s now voters’ rallying cry
stat
23d
What has actually caused the decline in drug overdose deaths?
stat
23d
STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
stat
23d
Have you been impacted by Epic’s actions?
stat
25d
The 4 stages of women’s heart health: New framework for doctors and patients
stat
Oct 19, 26
Merck KGaA makes noise in hematology with $1.1B Silence buy
biospace
Oct 19, 26
Merck KGaA bets on RNAi with $1.3B Silence buyout
biopharma dive
Oct 19, 26
Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep
biospace
Oct 19, 26
Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweep
biospace
Oct 19, 26
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
fiercebiotech
Oct 8, 26
On the move: 4 rare disease companies hiring now
biospace
Sep 22, 26
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
fiercebiotech
Sep 15, 26
Kairon Health raises $5M to use data to make patients healthier
endpoints
Sep 10, 26
A booming business on Wall Street would love more biotechs to quietly die
biopharma dive
Sep 10, 26
Opinion: John Fetterman’s post-stroke, politically problematic behaviors offer lessons about brain health on Capitol Hill
stat
Sep 4, 26
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
biopharma dive
Aug 31, 26
FDA OKs Takeda, Protagonist drug for rare blood cancer
biopharma dive
Aug 31, 26
Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
biospace
Aug 28, 26
FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder
fda press
Aug 25, 26
Amgen, academic centers weigh new FDA pilot to speed early drug trials
endpoints
Aug 13, 26
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
biospace
Aug 13, 26
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
Aug 11, 26
Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3
biospace
Aug 11, 26
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
fiercebiotech
← prev
page 1 of 2
next →